Eloralintide
LY3841136
Eloralintide is an investigational once-weekly amylin receptor agonist from Lilly, studied for obesity, with a published 48-week phase 2 trial behind it.
Regulatory status: Investigational. Phase 1 and phase 2 results are published, but it has no approval anywhere.
Default vial
10 mg
Default mix
2 mL
Reported range
1–9 mg (phase 2 arms)
Draw (U-100)
20 u
Investigational selective amylin receptor agonist. Unlike most of this library it has real published human data — a 48-week phase 2 trial in The Lancet — but it is not approved anywhere.
Where these numbers come from
A 48-week phase 2 trial (Lancet 2025) randomised fixed doses of 1, 3, 6 and 9 mg once weekly, plus 3→9 mg and 6→9 mg escalation arms. Investigational — no approved dose exists.
Dose ladder: The phase 2 escalation arms stepped 3 mg to 9 mg, or 6 mg to 9 mg
- Eloralintide, a selective amylin receptor agonist for obesity: 48-week phase 2 trial, Lancet 2025
- Eloralintide, a selective long-acting amylin receptor agonist: phase 1 proof of concept, Diabetes Obes Metab 2026
Reviewed October 2026
What it is
- A selective agonist at the amylin receptor — a different target from the GLP-1 drugs most people have heard of.
- Long-acting, designed for once-weekly subcutaneous injection.
- Amylin is a hormone the pancreas releases alongside insulin; it slows gastric emptying and signals satiety.
- Investigational use only.
How it is described to act
- 1
Given once weekly by subcutaneous injection in trial settings.
- 2
Reported to act at amylin receptors, including in the area postrema and other central satiety regions.
- 3
Because the target is not GLP-1, researchers have studied it partly on the premise that it may be better tolerated than incretin drugs.
- 4
In the phase 2 cohort this was associated with dose-dependent weight reduction over 48 weeks.
What the research has looked at
Phase 2 trial (48 weeks)
- A 48-week randomised, double-blind, placebo-controlled trial in 263 adults across 46 US centres tested fixed weekly doses of 1, 3, 6 and 9 mg plus two escalation arms (Lancet, 2025).
- The authors reported dose-dependent mean weight reductions, roughly 9% at 1 mg rising to about 20% at 9 mg, against roughly 0.4% on placebo.
- Nausea was the most common adverse event and did not rise cleanly with dose — investigators reported it in 64% of the 6 mg arm against 33% of the 9 mg arm, which is the kind of result that needs a larger trial to interpret.
- The trial was funded by Eli Lilly, the compound's developer.
Earlier work
- A phase 1 proof-of-concept study of once-weekly subcutaneous dosing has been published (Diabetes Obes Metab, 2026).
- The discovery and preclinical programme, including rat studies, is described in Mol Metab (2025).
Strength of evidence: Limited human evidence
Randomised phase 2 data exist and are published in a major journal, which puts this well ahead of most compounds in this library. It is still unapproved, and phase 3 results do not exist.
Some human data exist, but they are small, short, or not designed to answer the questions people ask online.
Reported cautions and unknowns
- Nausea and fatigue were the most frequently reported adverse events in phase 2, more common on the higher doses than on placebo.
- 48 weeks is the longest published exposure. Nothing is established beyond that.
- No phase 3 safety programme has reported, so the uncommon risks that larger trials surface are simply unknown.
References
- 1.Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial, Lancet (2025)
- 2.Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept, Diabetes Obes Metab (2026)
- 3.Eloralintide (LY3841136), a novel amylin receptor agonist: from discovery to clinical proof of concept, Mol Metab (2025)
Handling this vial
- Lyophilized vials are generally stored at 2–8 °C and kept out of light; once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after 28 days.
- Mix by aiming water down the vial wall and rolling gently — do not shake — and never re-freeze a reconstituted vial.
- Pep-Tidy cannot verify what is in your vial. Ask your supplier for a current Certificate of Analysis (HPLC/MS).
Eloralintide questions people ask
How do you reconstitute Eloralintide?
A common starting point for a 10 mg vial of Eloralintide is 2 mL of bacteriostatic water, which gives 5 mg per mL. Aim the water down the inside wall of the vial, let it dissolve on its own, and roll gently instead of shaking. Pep-Tidy's reconstitution calculator will recalculate the numbers for any other vial size or water volume you use.
How many units of Eloralintide is one dose?
At 5 mg per mL, that works out to about 20 units on a U-100 insulin syringe for a 1000 mcg dose. Change the vial size, water volume, or target dose in the calculator and the syringe reading updates with it. This is arithmetic, not a dosing recommendation.
What dosing schedule is reported for Eloralintide?
Published and community sources describe 1–9 mg (phase 2 arms), subcutaneous, once weekly, typically run 24 weeks on. These figures describe what has been reported, not what anyone should take — talk to a licensed clinician first.
How should Eloralintide be stored?
Lyophilized Eloralintide vials are generally kept at 2–8 °C and out of light. Once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after about 28 days. Never re-freeze a reconstituted vial and never shake it.
Read this before you act on anything above
Everything on this page is a summary of what other people have published — it is not medical advice, not a recommendation, and not a dosing instruction. Reported dose ranges describe what appears in the literature or in community protocols, not what anyone should take. Talk to a licensed clinician before using any peptide.